SARS-CoV-2/ Influenza A Virus/ Influenza B Virus Nucleic Acid Detection Kit (Fluorescence RT-PCR)

TRI-J17M1

SARS-CoV-2/ Influenza A Virus/ Influenza B Virus Nucleic Acid Detection Kit (Fluorescence RT-PCR)

2619.2 €

TRI-J17S1

SARS-CoV-2/ Influenza A Virus/ Influenza B Virus Nucleic Acid Detection Kit (Fluorescence RT-PCR)

1428.5 €

TRI-J36L1

SARS-CoV-2/Influenza A Virus/Influenza B Virus Nucleic Acid Multiple Detection Kit (Fluorescence PCR)

4796.48 €

HY-144770

SARS-CoV-2-IN-13

SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally[1].

1039.04 €

HY-144771

SARS-CoV-2-IN-14

SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.39 μM. SARS-CoV-2-IN-14 is a niclosamide analogue. SARS-CoV-2-IN-14 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally[1].

129.93 €

HY-144772

SARS-CoV-2-IN-15

SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.49 μM. SARS-CoV-2-IN-15 is a niclosamide analogue. SARS-CoV-2-IN-15 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally[1].

Ask for quotation